prof. Valerie Fonteyne

Journal Article
A1
open access

Genomic determinants associated with modes of progression and patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer

Philip Sutera, Yang Song, Amol C. Shetty, Keara English, Kim Van der Eecken, Ozan Cem Guler, Jarey Wang, Yufeng Cao, Soha Bazyar, Sofie Verbeke (UGent) , et al.

(2025) EUROPEAN UROLOGY ONCOLOGY. 8(1). p.111-118

Add to list

Journal Article
A1
open access

Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer : a phase 2 trial : results of secondary endpoints

Flor Verghote (UGent) , Elke Rammant (UGent) , Piet Dirix, Charles Van Praet (UGent) , Charlien Berghen, Sara Junius, Nick Liefhooghe, Leen Noé, Piet Ost (UGent) , Karel Decaestecker (UGent) , et al.

(2025) EUROPEAN UROLOGY FOCUS.

Add to list

Journal Article
A2
open access

Can PET-CT improve the staging and outcome of patients with muscle-invasive bladder cancer?

Valerie Fonteyne (UGent) , Flor Verghote (UGent) , Camille Berquin (UGent) , Daan De Maeseneer (UGent) , Geert Villeirs (UGent) and Kathia De Man (UGent)

(2024) AME CLINICAL TRIALS REVIEW. 2.

Add to list

Journal Article
A1
open access

Retrospective analysis of multiparametric MRI in predicting complete pathologic response of neo-adjuvant chemotherapy in bladder cancer

Daan De Maeseneer (UGent) , Pieter De Visschere (UGent) , Mats Van den broecke, Felix Delbare, Geert Villeirs (UGent) , Sofie Verbeke (UGent) , Valerie Fonteyne (UGent) , Charles Van Praet (UGent) , Karel Decaestecker (UGent) , Alexander Decruyenaere (UGent) , et al.

(2024) BMC MEDICAL IMAGING. 24(1).

Add to list

Adjuvant EBRT for muscle-invasive bladder cancer : phase 2 trial secondary analysis (NCT02397434)

Flor Verghote (UGent) , Piet Dirix, Charles Van Praet (UGent) , Charlien Berghen, Ben Vanneste (UGent) , Sara Junius, Nick Liefhooghe, Leen Noé, Gert De Meerleer, Piet Ost (UGent) , et al.

(2024) RADIOTHERAPY AND ONCOLOGY. In Radiotherapy and Oncology 194(Supplement 1). p.S2308-S2311

Add to list

Moderate hypofractionated radiotherapy for prostate cancer : 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial

Valerie Fonteyne (UGent) , C Berghen, Charles Van Praet (UGent) , Barbara Vanderstraeten (UGent) , Sofie Verbeke (UGent) , Geert Villeirs (UGent) , Roos Colman (UGent) , Ben Vanneste (UGent) , Piet Ost (UGent) , G De Meerleer, et al.

(2024) RADIOTHERAPY AND ONCOLOGY. 193.

Add to list

Journal Article
A1
open access

Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer : a qualitative study exploring patient priorities and counselling needs when making a treatment choice

Flor Verghote (UGent) , Charles Van Praet (UGent) , Camille Berquin (UGent) , Nicolaas Lumen (UGent) , Karel Decaestecker (UGent) , Ben Vanneste (UGent) , Elke Rammant (UGent) and Valerie Fonteyne (UGent)

(2024) BMC CANCER. 24(1).

Add to list

Journal Article
A1
open access

Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy : real-world data from the E2-RADIatE OligoCare cohort

Renée Bultijnck (UGent) , Mieke Van Hemelrijck, Valerie Fonteyne (UGent) , Lorenzo Livi, Barbara Alicja Jereczek-Fossa, Hossein Hemmatazad, Michael Mayinger, Heike Peulen, Luc Verbeke, Sara Ramella, et al.

(2024) CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 45.

Add to list

PI-RADS 5 in prostate magnetic resonance imaging : how important is intraprostatic invasive behavior?

Ottavia Battaglia, Pieter De Visschere (UGent) , Sifrid Hendrickx (UGent) , Valerie Fonteyne (UGent) , Sofie Verbeke (UGent) , Charles Van Praet (UGent) and Geert Villeirs (UGent)

(2024) European Congress of Radiology 2024 (ECR 2024), Abstracts.

Add to list

PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : acute toxicity of a randomized phase 2 trial

Piet Ost (UGent) , Shankar Siva, Sigmund Brabrand, Piet Dirix, Nick Liefhooghe, François-Xavier Otte, Alfonso Gomez-Iturriaga, Wouter Everaerts, Mohamed Shelan, Antonio Conde-Moreno, et al.

(2024) EUROPEAN UROLOGY ONCOLOGY. 7(3). p.462-468

Academic Bibliography

prof. Valerie Fonteyne

Genomic determinants associated with modes of progression and patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer

Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer : a phase 2 trial : results of secondary endpoints

Can PET-CT improve the staging and outcome of patients with muscle-invasive bladder cancer?

Retrospective analysis of multiparametric MRI in predicting complete pathologic response of neo-adjuvant chemotherapy in bladder cancer

Adjuvant EBRT for muscle-invasive bladder cancer : phase 2 trial secondary analysis (NCT02397434)

Moderate hypofractionated radiotherapy for prostate cancer : 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial

Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer : a qualitative study exploring patient priorities and counselling needs when making a treatment choice

Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy : real-world data from the E2-RADIatE OligoCare cohort

PI-RADS 5 in prostate magnetic resonance imaging : how important is intraprostatic invasive behavior?

PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : acute toxicity of a randomized phase 2 trial

Contents

Support

Contact